APA (7th ed.) Citation

Pozo-Rosich, P., Detke, H. C., Wang, S., Doležil, D., Li, L. Q., Aurora, S. K., & Reuter, U. (2022). Long-term treatment with galcanezumab in patients with chronic migraine: Results from the open-label extension of the REGAIN study. Current medical research and opinion, 38(5), 731-742. https://doi.org/10.1080/03007995.2022.2059975

Chicago Style (17th ed.) Citation

Pozo-Rosich, Patricia, Holland C. Detke, Shufang Wang, David Doležil, Lily Q. Li, Sheena K. Aurora, and Uwe Reuter. "Long-term Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-label Extension of the REGAIN Study." Current Medical Research and Opinion 38, no. 5 (2022): 731-742. https://doi.org/10.1080/03007995.2022.2059975.

MLA (9th ed.) Citation

Pozo-Rosich, Patricia, et al. "Long-term Treatment with Galcanezumab in Patients with Chronic Migraine: Results from the Open-label Extension of the REGAIN Study." Current Medical Research and Opinion, vol. 38, no. 5, 2022, pp. 731-742, https://doi.org/10.1080/03007995.2022.2059975.